BiondVax ’s Phase IIb trial for flu vaccine meets primary endpoints
Israel-based BiondVax Pharmaceuticals and the UNISEC consortium have announced positive data from the Phase IIb clinical trial of universal flu vaccine candidate, M-001. (Source: Drug Development Technology)
Source: Drug Development Technology - July 23, 2017 Category: Pharmaceuticals Source Type: news
Researchers find South African child in HIV remission for nine years
Scientists at the Ninth International AIDS conference on HIV Science held on 24th July in Paris have reported that a South African child diagnosed with HIV at birth has been healthy and in remission for approximately nine years without any treatment. (Source: Drug Development Technology)
Source: Drug Development Technology - July 23, 2017 Category: Pharmaceuticals Source Type: news
Gold Nanoparticle Applications and Characterisation by Nanoparticle Tracking Analysis
Gold nanoparticles are one of the most popular and extensively researched type of nanoparticle. (Source: Drug Development Technology)
Source: Drug Development Technology - July 21, 2017 Category: Pharmaceuticals Source Type: news
Deals this week: AntriaBio, Race Oncology, Invenra
AntriaBio has announced the private placement of 4.5 million shares of its common stock, priced at $1 a share, to raise $4.5m in gross proceeds. (Source: Drug Development Technology)
Source: Drug Development Technology - July 20, 2017 Category: Pharmaceuticals Source Type: news
CTD Holdings begins dosing in Phase I/II trial of Trappsol Cyclo to treat NPC
CTD Holdings has commenced patient dosing in a Phase I/II clinical trial of its intravenous drug candidate Trappsol Cyclo for the treatment of patients in Europe with Niemann-Pick disease type C (NPC). (Source: Drug Development Technology)
Source: Drug Development Technology - July 20, 2017 Category: Pharmaceuticals Source Type: news
Celyad commences Phase I trial of CYAD-01 to treat colorectal cancer
Belgian biopharmaceutical firm Celyad has commenced a Phase I clinical trial (SHRINK) of its product candidate CYAD-01 (CAR-T NKG2D) for the treatment of patients with metastatic colorectal cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - July 20, 2017 Category: Pharmaceuticals Source Type: news
Nektar reports positive top-line results from HAP study of NKTR-181 for chronic pain
US-based biopharmaceutical firm Nektar Therapeutics has reported positive top-line results from an oral human abuse potential (HAP) study of its opioid analgesic, NKTR-181, for chronic pain. (Source: Drug Development Technology)
Source: Drug Development Technology - July 19, 2017 Category: Pharmaceuticals Source Type: news
Tiziana enrols first patient in Phase IIa trial of milciclib to treat HCC
UK-based biotechnology firm Tiziana Life Sciences has started patient enrolment in a Phase IIa clinical trial of milciclib for the treatment of hepatocellular carcinoma (HCC) patients. (Source: Drug Development Technology)
Source: Drug Development Technology - July 19, 2017 Category: Pharmaceuticals Source Type: news
TopiVert and Onynx initiate clinical trials of NSKI drugs
UK-based biotechnology firm TopiVert has initiated clinical trials of two of its narrow spectrum kinase inhibitor (NSKI) drug candidates, TOP1288 and TOP1630, with support from contract research organisation (CRO) Onyx Scientific. (Source: Drug Development Technology)
Source: Drug Development Technology - July 19, 2017 Category: Pharmaceuticals Source Type: news
Sunesis starts dosing in Phase Ib/II trial of SNS-062 for B-cell malignancies
Sunesis Pharmaceuticals has started dosing patients in a Phase Ib/II clinical trial of SNS-062 to treat patients with B-cell malignancies such as chronic lymphocytic leukaemia (CLL), small lymphocytic leukaemia, Waldenstrom ’s macroglobulinemia and ma… (Source: Drug Development Technology)
Source: Drug Development Technology - July 18, 2017 Category: Pharmaceuticals Source Type: news
Can-Fite commences Phase II trial of namodenoson for NAFLD/NASH
Israeli biotechnology firm Can-Fite BioPharma is set to commence patient enrolment for a Phase II clinical trial of namodenoson to treat non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), following the successful conc … (Source: Drug Development Technology)
Source: Drug Development Technology - July 18, 2017 Category: Pharmaceuticals Source Type: news
CPP initiates NCI-funded Phase II trial of CPP-1X for gastric cancer
US-based Cancer Prevention Pharmaceuticals (CPP) has initiated a Phase II clinical trial of CPP-1X for the treatment of precancerous gastric lesion patients who are at high gastric cancer risk. (Source: Drug Development Technology)
Source: Drug Development Technology - July 18, 2017 Category: Pharmaceuticals Source Type: news
Powerful Benchtop Spectrometer for Small Spot Analysis
Supplier of analytical X-ray instrumentation and software PANalytical has announced the introduction of a new Epsilon 1 X-ray fluorescence (XRF) spectrometer. (Source: Drug Development Technology)
Source: Drug Development Technology - July 18, 2017 Category: Pharmaceuticals Source Type: news
The ImmunoPrecise Rapid Prime System Reduces the Immunization Stage of Hybridoma Production to 18 Days
(Source: Drug Development Technology)
Source: Drug Development Technology - July 18, 2017 Category: Pharmaceuticals Source Type: news
Sartorius Lab Instrument's Cubis ® Balance Range Meets the Cleanability Requirements of the Pharmaceutical Industry
Balances in Satorius Lan Instrument's Cubis ® product range have been designed for the demanding pharmaceutical environment, which is regulated by good manufacturing practices (GMP) and good laboratory practices (GLP). (Source: Drug Development Technology)
Source: Drug Development Technology - July 18, 2017 Category: Pharmaceuticals Source Type: news
